Get started
Author

Maria Mellinas‐Gomez

A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer
2015 · Stephan A Ohnmacht, Chiara Marchetti, et al. · Scientific Reports · 118
PDF
γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
2012 · Jenny Wu, Peter H. Clingen, et al. · Clinical Cancer Research · 64
ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers
2016 · F. Zammarchi, S. Chivers, et al. · European Journal of Cancer · 16
hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.
2016 · Francesca Zammarchi, Simon Corbett, et al. · Blood · 13
Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours
2015 · Maria Mellinas-Gomez, Victoria J. Spanswick, et al. · BMC Veterinary Research · 9
PDF
Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors
2017 · Francesca Zammarchi, Halla W. Reinert, et al. · Cancer Research · 5
Application of diffusion‐edited and solvent suppression 1H‐NMR to the direct analysis of markers in valerian‐hop liquid herbal products
2016 · Jose M. Prieto, Maria Mellinas‐Gomez, et al. · Phytochemical Analysis · 4
PDF
Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSMA-expressing prostate cancers
2017 · Francesca Zammarchi, Simon Chivers, et al. · Cancer Research · 1
Supplementary Figure 3 from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
2023 · Jenny Wu, Peter H. Clingen, et al.
Supplementary Figure 1 from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
2023 · Jenny Wu, Peter H. Clingen, et al.
Supplementary Figure 2 from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
2023 · Jenny Wu, Peter H. Clingen, et al.
Supplementary Figure Legend from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
2023 · Jenny Wu, Peter H. Clingen, et al.
PDF
Data from γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)
2023 · Jenny Wu, Peter H. Clingen, et al.
Additional file 1: Table S1. of Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours
2015 · Mellinas-Gomez, Maria, Spanswick, Victoria, et al. · Figshare
Abstract 2536: Investigation of the effect of the sequence selective DNA minor groove cross-linking agent SG2000 (SJG-136) on canine tumor cells in vitro and in vivo
2011 · Maria Mellinas-Gomez, Stephen Baines, et al. · Cancer Research
281 Investigation of the effect of the sequence-selective DNA cross-linking agent SJG-136 on canine tumour cells in vitro
2010 · M. Mellinas-Gomez, V.J. Spanswick, et al. · European Journal of Cancer Supplements
PDF
Works count: 18
Citation count: 230
H-index: 5
I10-index: 4
Year
Topic
Type